Clinical trials: Neurodegenerative Disorders
Dementia, Alzheimer Type, Problem Behavior
Home Evaluation of Exit Barriers in Wandering
Main hypothesis. Floor and door visual exit barriers will decrease exit-seeking wandering (exit door approaches) proximal to exit doorways by persons with dementia who wander.
- Trial name
- HEEBW (NCT00997425)
- Testing
- Door cover/Floor cover
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- US Department of Veterans Affairs
Parkinsonian Syndrome, Parkinson Disease(PD)
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
This is a multicenter, open-label, non-controlled, non-randomized, phase 3 clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical…
- Conditions
- Parkinsonian Syndrome, Parkinson Disease(PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT04193527
- Testing
- DaTSCAN™ Ioflupane (123I) Injection
- Where
- 10 sites in China
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Alzheimer Disease, Cognitive Dysfunction
Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type
A Randomized Pivotal Study of RenewTM NCP-5 for the Treatment of Mild Cognitive Impairment due to Alzheimer's Disease or Mild Dementia of the Alzheimer's Type is a pivotal, single blind, parallel design, multi-site study intends…
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Mild Cognitive Impairment, Mild Dementia
- Trial name
- NCT03721705
- Testing
- Renew NCP-5
- Where
- 12 sites in United States, Ireland and 1 more
- Volunteers
- 190 people
- Sponsor
- Renew Research, LLC
Alzheimer Disease, Parkinson Disease
Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients
Annovis is conducting a clinical study to investigate Posiphen in patients with Early Alzheimer's Disease (AD) and Early Parkinson's Disease (PD). Investigators are looking to recruit 68 patients in two parts of the study.
- Trial name
- NCT04524351
- Testing
- Posiphen
- Where
- 13 sites in United States
- Volunteers
- 75 people
- Sponsor
- Annovis Bio Inc.
Parkinson Disease
Connect.Parkinson: Connecting Individuals With Parkinson Disease to Specialists in Their Homes
Connect.Parkinson is a randomized comparative effectiveness study, comparing usual care enhanced with educational materials to usual care, educational materials, and the delivery of specialty care via telemedicine into patient's…
- Trial name
- NCT02038959
- Testing
- Virtual Visits
- Where
- 20 sites in United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Huntington Disease, Parkinson Disease
Measurement and Modification of Threat Interpretation Bias in Neurodegenerative Movement Disorders (Aims 2 & 3)
The purpose of this study is conduct a pilot open trial of a web-based cognitive bias modification intervention to reduce anxiety symptoms in persons with Huntington's disease and persons with Parkinson's disease.
- Trial name
- NCT05126862
- Testing
- MindTrails
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Virginia
Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the Rotigotine patch in subjects with advanced-stage idiopathic Parkinson's Disease.
- Trial name
- SP715 (NCT00594386)
- Testing
- Rotigotine
- Where
- 41 sites in United States, Canada
- Volunteers
- 258 people
- Sponsor
- UCB Pharma
Lewy Body Disease, Parkinson Disease
A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology
The purpose of study is to demonstrate the pharmacodynamic (PD) effects of E2027 on cerebrospinal fluid (CSF) cyclic guanosine monophosphate (cGMP) in participants with DLB and PDD with and without amyloid copathology after 9…
- Trial name
- NCT04764669
- Testing
- E2027
- Where
- 14 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Eisai Inc.
Alzheimer's Disease
Evaluation of PET Scan Timing Relative to AV-45 Injection Time
This study will re-read 10-minute positron emission tomography (PET) scans acquired in previous clinical studies of AV-45 at 30 and 50 minutes after injection and compare the results.
- Trial name
- NCT01565356
- Testing
- florbetapir F 18
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Tourette Syndrome, Chronic Tic Disorder
Median Nerve Stimulation for Tourette Syndrome and Chronic Tic Disorder
Tourette syndrome (TS) and chronic tic disorder (CTD) are neurodevelopmental disorders that impact approximately 1% of 5-18 year olds worldwide.
- Trial name
- NeSTS (NCT05269953)
- Testing
- Active stimulation
- Where
- United Kingdom
- Volunteers
- 135 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Parkinson Disease
Cartesia eXTend 3D Study
The purpose of the study is to document patient outcomes including effectiveness for Boston Scientific Corporation's Vercise Cartesia 16-contact Directional Lead(s) (X/HX) with Deep Brain Stimulation (DBS) systems for the…
- Trial name
- eXTend 3D (NCT04577651)
- Testing
- 16-contact Directional Deep Brain Stimulation
- Where
- 10 sites in Germany, Netherlands and 1 more
- Volunteers
- 58 people
- Sponsor
- Boston Scientific Corporation
Parkinson's Disease
A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants
The purpose of this study is to evaluate the long-term safety of TVP-1012 (1 mg/day) in Japanese participants with early Parkinson's disease.
- Trial name
- NCT02337751
- Testing
- TVP-1012 1mg
- Where
- 56 sites in Japan
- Volunteers
- 198 people
- Sponsor
- Takeda
Alzheimer's Disease
A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine whether multiple dose administration is safe and well tolerated in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00945672
- Testing
- PF-04360365 10 mg/kg, PF-04360365 7.5 mg/kg
- Where
- 4 sites in Sweden
- Volunteers
- 36 people
- Sponsor
- Pfizer
Neuropathy, Paraneoplastic
MC-5A for Chemotherapy Induced Peripheral Neuropathy
Painful chemotherapy induced peripheral neuropathy (CIPN) is a common complication of cancer therapy with few treatment options.
- Trial name
- NCT01261780
- Testing
- MC-5A
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Wisconsin, Madison
Parkinson Disease
Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).
The general aim of this study is to obtain long-term safety and tolerability data on pramipexole ER, in daily doses from 0.375mg to 4.5mg once daily (q.d), in patients who have previously completed a pramipexole double-blind…
- Trial name
- NCT00601523
- Testing
- Pramipexole
- Where
- 119 sites in United States, Austria and 13 more
- Volunteers
- 511 people
- Sponsor
- Boehringer Ingelheim
Dementia, Dementia, Vascular
Palliative Care for Persons With Late-stage Alzheimer's and Related Dementias and Their Caregivers
Millions of Americans have late-stage Alzheimer's and related dementias (ADRD), causing suffering due to loss of awareness of self and family, progressive dependency, physical and neuropsychiatric symptoms, and physical…
- Conditions
- Dementia, Dementia, Vascular, Dementia With Lewy Bodies, Dementia Frontal
- Trial name
- ADRD-PC (NCT04948866)
- Testing
- ADRD-PC Program
- Where
- 5 sites in United States
- Volunteers
- 884 people
- Sponsor
- University of North Carolina, Chapel Hill
Alzheimer's Disease
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as…
- Trial name
- ENGAGE (NCT02477800)
- Testing
- Aducanumab (BIIB037)
- Where
- 181 sites in United States, Australia and 12 more
- Volunteers
- 1,653 people
- Sponsor
- Biogen
Early Parkinson Disease
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706
This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving…
- Trial name
- NCT03655236
- Testing
- K0706
- Where
- 78 sites in United States, Hungary and 4 more
- Volunteers
- 513 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Headache, Tumor
Dexmedetomidine and Propofol for Pediatric MRI Sedation
The purpose of this study is to compare the results of combining two anesthetic medications (dexmedetomidine and propofol) in low doses with a standard dose of a single drug that is commonly used to provide sedation/anesthesia…
- Conditions
- Headache, Tumor, Seizure Disorder, Neurofibromatoses
- Trial name
- NCT03513757
- Testing
- propofol, Dexmedetomidine, Glycopyrrolate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medical College of Wisconsin
Alzheimer's Disease
Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
The purpose of this study is to assess the safety, tolerability, and immunogenicity of ACC-001, an investigational vaccine, in subjects with mild to moderate Alzheimer's disease in Japan.
- Trial name
- NCT00959192
- Testing
- ACC-001, QS-21
- Where
- 9 sites in Japan
- Volunteers
- 32 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.